China's crown disease "grab the drug tide"Capital Beijing will uniformly distribute Paxlovid (China known as "Namartvilk/Litnaville") and provide training to the city's community health service center, but the specific delivery time is unclear.
Comprehensive Xinjing News and Health Times reported that on the Internet (December 25), it was circulated on the Internet that Beijing will recently uniformly distribute PaxLovid to various community health service centers.Guide patients with coronary disease in the jurisdiction for antiviral treatment.Many community health service centers in Beijing confirmed on Monday (26th) that they have received notice from participating in PaxLovid application training, but the drug has not been delivered.
The relevant person in charge of the community health service center revealed that the emergency training of the Paxlovid application is a unified deployment of the city and will be carried out online on Monday afternoon.I don't know the specific time.
A community doctor said that the unit had already reserved medicines, but the specific use indications and other issues need to be trained.
However, when the Hong Kong media "Hong Kong 01" called the Beijing Health and Health Commission 12320 on Monday on Monday, the staff said that "no such notice is received for the time being, the specific situation is not very clear, or it may be whetherInformation delays may be followed. "The report also said that the staff of the Beijing Centers for Disease Control and Administration and Beijing Government Affairs 12345 also responded that they did not query the relevant information.
Another source revealed that before, the China National Health and Health Commission has organized "anti -new coronary virus drug Nimaltwe/Litnavilian combination packaging use video training meeting".
PaxLovid was developed and produced by the US Pfizer. In February 2022, the China National Drug Administration was approved to approve its import registration.According to the approved information, PaxLovid is the treatment of oral small molecular crown disease. In the diagnosis and treatment plan issued by the China Health and Health Commission on March 15, the applicable population of PaxLovid is light and ordinary as a mild and common type within five days of the disease and progress is accompanied by progress.Adults and adolescents with high -risk factors.
China's crown disease has severely increased the demand for the people against virus drugs. The situation of "one medicine is difficult to find" in pharmacies and hospitals in various places, and the public has sought online sales channels to buy medicines.Some people even purchase other places through black market channels, but they have not been allowed to sell PAXLOVID such as PAXLOVID.
